Stockscreener 앱 받기
0.18
6.76%
0.0114
시간 외 거래:
.18
전일 마감가:
$0.1686
열려 있는:
$0.17
하루 거래량:
353.91K
Relative Volume:
0.58
시가총액:
$3.65M
수익:
-
순이익/손실:
$-20.26M
주가수익비율:
-0.0211
EPS:
-8.54
순현금흐름:
$-8.25M
1주 성능:
+5.88%
1개월 성능:
-5.76%
6개월 성능:
-50.55%
1년 성능:
-90.22%
1일 변동 폭
$0.17
$0.18
1주일 범위
$0.1648
$0.19
52주 변동 폭
$0.1617
$3.43
Oragenics Inc Stock (OGEN) Company Profile
명칭
Oragenics Inc
전화
813-286-7900
주소
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
OGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.18 | 3.65M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc 주식(OGEN)의 최신 뉴스
Oragenics, Inc. to Host Management Update Webinar on May 20, 202 - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May - GlobeNewswire
Oragenics: Q1 Earnings Snapshot - New Haven Register
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics Appoints New CEO and Amends Employment Terms By Investing.com - Investing.com Nigeria
Oragenics Appoints New CEO and Amends Employment Terms - Investing.com Australia
Oragenics Appoints Janet Huffman as CEO and CFO - TipRanks
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brai - GuruFocus
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN Stock News - GuruFocus
Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management - Nasdaq
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference - GlobeNewswire
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
OGEN stock touches 52-week low at $0.19 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com
OGEN stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com Australia
Oragenics reports progress in concussion drug development By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline By Investing.com - Investing.com South Africa
Oragenics reports progress in concussion drug development - Investing.com
Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress - MarketScreener
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - The Manila Times
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
Investornewsbreaks Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status - MENAFN.COM
CEMATRIX To Report Fourth Quarter and 2024 Year End Results on March 26, 2025 - The Manila Times
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - TradingView
Oragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit Opinion - Nasdaq
Going Concern Alert: Oragenics Brain Treatment Pipeline Faces Critical Financial Test - StockTitan
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles - Investing.com Australia
Oragenics Inc (OGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.10%
자본화:
|
볼륨(24시간):